The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results